February 1987
Volume 28, Issue 2
Free
Articles  |   February 1987
Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.
Author Affiliations
  • P C Maudgal
    Eye Research Laboratory, Ophthalmological Clinic, Katholieke Universiteit, Leuven, Belgium.
  • E De Clercq
    Eye Research Laboratory, Ophthalmological Clinic, Katholieke Universiteit, Leuven, Belgium.
  • P Huyghe
    Eye Research Laboratory, Ophthalmological Clinic, Katholieke Universiteit, Leuven, Belgium.
Investigative Ophthalmology & Visual Science February 1987, Vol.28, 243-248. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P C Maudgal, E De Clercq, P Huyghe; Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.. Invest. Ophthalmol. Vis. Sci. 1987;28(2):243-248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

A new acyclic adenosine analogue, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], was evaluated for its efficacy in the topical treatment of experimental keratitis caused by the thymidine kinase-positive (TK+) and thymidine kinase-deficient (TK-) herpes simplex virus type 1 (HSV-1) strains. In the treatment of TK+ HSV-1 keratitis, 0.2% (S)-HPMPA eyedrops were as effective as the reference compounds, 0.2% (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and 0.2% 5-(2-chloroethyl)-2'-deoxy-uridine (CEDU) eyedrops. The three compounds produced a statistically significant healing effect, as compared with placebo eyedrops. In the treatment of keratitis caused by the TK- HSV-1 strain, 0.2%BVDU and 0.2% CEDU eyedrops did not differ from placebo eyedrops, whereas 0.2% (S)-HPMPA eyedrops exerted a highly significant healing effect.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×